Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABLYF Ablynx	$50.63	$50.63	$12.50 ▼ $55.04	$3.81B	1.99	5,063 shs	N/A
ALLO Allogene Therapeutics	$1.28 +1.6%	$1.23	$0.86 ▼ $3.78	$279.98M	0.31	3.33 million shs	2.91 million shs
BOLD Boundless Bio	$1.18 -48.7%	$59.97	$1.00 ▼ $4.72	$26.64M	-1.34	102,772 shs	96,520 shs
ONCE Spark Therapeutics	$0.18	$113.43	$34.53 ▼ $114.20	$6.94M	2.05	891,560 shs	N/A
PRTO Proteon Therapeutics	$3.05 -2.2%	$19.37	$0.22 ▼ $3.94	$67.65M	0.6	1.11 million shs	118,209 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABLYF Ablynx	0.00%	0.00%	0.00%	0.00%	0.00%
ALLO Allogene Therapeutics	0.00%	+7.56%	-8.57%	-11.72%	-46.44%
BOLD Boundless Bio	0.00%	+11.85%	+7.27%	-3.28%	-71.97%
ONCE Spark Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
PRTO Proteon Therapeutics	-2.24%	+5.54%	-7.29%	-21.99%	+43.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABLYF Ablynx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ALLO Allogene Therapeutics	3.4664 of 5 stars	4.5	1.0	0.0	0.0	2.7	3.3	0.6
BOLD Boundless Bio	2.7779 of 5 stars	3.1	5.0	0.0	0.0	0.6	1.7	1.3
ONCE Spark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRTO Proteon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABLYF Ablynx	0.00	N/A	N/A	N/A
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	559.72% Upside
BOLD Boundless Bio	2.25	Hold	$4.00	238.98% Upside
ONCE Spark Therapeutics	0.00	N/A	N/A	N/A
PRTO Proteon Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ALLO, BOLD, ABLYF, ONCE, and PRTO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	BOLD Boundless Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
5/28/2025	BOLD Boundless Bio	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$15.00 ➝ $3.00
5/27/2025	BOLD Boundless Bio	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/15/2025	ALLO Allogene Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/14/2025	ALLO Allogene Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $7.00
5/14/2025	ALLO Allogene Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$12.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABLYF Ablynx	$62.73M	60.74	N/A	N/A	$2.71 per share	18.68
ALLO Allogene Therapeutics	$20K	13,998.72	N/A	N/A	$2.01 per share	0.64
BOLD Boundless Bio	N/A	N/A	N/A	N/A	$6.76 per share	N/A
ONCE Spark Therapeutics	$64.72M	0.11	N/A	N/A	$13.15 per share	0.01
PRTO Proteon Therapeutics	N/A	N/A	N/A	N/A	($0.06) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABLYF Ablynx	-$122.67M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ALLO Allogene Therapeutics	-$257.59M	-$1.23	N/A	N/A	N/A	N/A	-52.98%	-41.28%	8/6/2025 (Estimated)
BOLD Boundless Bio	-$65.36M	N/A	0.00	N/A	N/A	N/A	-41.60%	-34.53%	N/A
ONCE Spark Therapeutics	-$78.82M	-$2.11	N/A	N/A	N/A	-358.41%	-59.10%	-33.13%	N/A
PRTO Proteon Therapeutics	-$20.73M	-$1.15	N/A	N/A	N/A	N/A	N/A	-118.68%	N/A

Latest ALLO, BOLD, ABLYF, ONCE, and PRTO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	N/A	ALLO Allogene Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/9/2025	Q1 2025	BOLD Boundless Bio	-$0.68	-$0.71	-$0.03	-$0.71	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABLYF Ablynx	N/A	N/A	N/A	N/A	N/A
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
BOLD Boundless Bio	N/A	N/A	N/A	N/A	N/A
ONCE Spark Therapeutics	N/A	N/A	N/A	N/A	N/A
PRTO Proteon Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABLYF Ablynx	N/A	N/A	N/A
ALLO Allogene Therapeutics	N/A	9.71	9.71
BOLD Boundless Bio	0.35	22.15	22.15
ONCE Spark Therapeutics	0.35	4.67	4.35
PRTO Proteon Therapeutics	N/A	5.98	5.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABLYF Ablynx	N/A
ALLO Allogene Therapeutics	83.63%
BOLD Boundless Bio	N/A
ONCE Spark Therapeutics	88.37%
PRTO Proteon Therapeutics	23.03%

Insider Ownership

Company	Insider Ownership
ABLYF Ablynx	N/A
ALLO Allogene Therapeutics	13.20%
BOLD Boundless Bio	21.10%
ONCE Spark Therapeutics	6.00%
PRTO Proteon Therapeutics	45.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABLYF Ablynx	N/A	75.25 million	N/A	Not Optionable
ALLO Allogene Therapeutics	310	218.73 million	189.86 million	Optionable
BOLD Boundless Bio	207	22.39 million	17.66 million	No Data
ONCE Spark Therapeutics	368	38.52 million	N/A	No Data
PRTO Proteon Therapeutics	17	22.18 million	N/A	Not Optionable

ALLO, BOLD, ABLYF, ONCE, and PRTO Headlines

Recent News About These Companies

ProQR Therapeutics price target raised to $4 from $2.50 at Chardan

November 9, 2024 | markets.businessinsider.com

Protara Therapeutics (TARA) Earnings Dates & Reports

November 1, 2024 | investing.com

ProQR Therapeutics upgraded to Strong Buy from Outperform at Raymond James

October 29, 2024 | markets.businessinsider.com

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday

October 28, 2024 | msn.com

ProQR Announces Major Share Offering Agreement

October 25, 2024 | markets.businessinsider.com

Seaport raises $225m to advance portfolio of neuropsychiatric prodrugs

October 22, 2024 | msn.com

Understanding Neurodegenerative Disease with Prion Research

September 13, 2024 | the-scientist.comT

Prodrugs and patents: Enhancing therapy adherence and reducing side effects

September 11, 2024 | msn.com

iPhone 13 Pro vs. iPhone 16 Pro: 65+ Upgrades to Expect

September 8, 2024 | macrumors.comM

PS5 Pro: the latest on rumored specs, price, and release date speculation

August 30, 2024 | techradar.comT

Rapport Therapeutics Seeks IPO For CNS Treatment Programs

May 22, 2024 | seekingalpha.com

PTC Therapeutics: Q1 Earnings Snapshot

April 25, 2024 | timesunion.comT

Protara Therapeutics Inc (TARA)

April 24, 2024 | investing.com

iPad Pro

February 2, 2024 | macrumors.comM

Esperion Therapeutics Inc ESPR

November 5, 2023 | morningstar.comM

The Latest Analyst Ratings for Revance Therapeutics

September 20, 2023 | benzinga.com

ENLV - Enlivex Therapeutics Ltd.

June 6, 2023 | finance.yahoo.com

Prelude Therapeutics Insider Trades Send a Signal

May 25, 2023 | benzinga.com

Global Protein Therapeutics Market Report 2023: Development of Plasma Derived Therapies Drives Growth

May 22, 2023 | benzinga.com

The best iPhone 14 Pro deals for May 2023

May 18, 2023 | techradar.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

D-Wave Is Rising Again Despite Dilution—What’s the Deal?
By Nathan Reiff | July 7, 2025
View D-Wave Is Rising Again Despite Dilution—What’s the Deal?
Addition by Subtraction: Intel’s New Strategy Energizes Investors
By Jeffrey Neal Johnson | June 27, 2025
View Addition by Subtraction: Intel’s New Strategy Energizes Investors
The Apple Comeback Will Be Better Than the Setback
By Gabriel Osorio-Mazilli | July 4, 2025
View The Apple Comeback Will Be Better Than the Setback
Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
By Leo Miller | June 14, 2025
View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
These 3 Dividend Stocks Are Not Concerned With Tariff Noise
By Thomas Hughes | July 11, 2025
View These 3 Dividend Stocks Are Not Concerned With Tariff Noise

ALLO, BOLD, ABLYF, ONCE, and PRTO Company Descriptions

Ablynx OTCMKTS:ABLYF

$50.63 0.00 (0.00%)

As of 04/30/2019

Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

Allogene Therapeutics NASDAQ:ALLO

$1.28 +0.02 (+1.59%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$1.29 +0.01 (+0.78%)

As of 07/11/2025 07:42 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Boundless Bio NASDAQ:BOLD

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.

Spark Therapeutics NASDAQ:ONCE

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.

Proteon Therapeutics NASDAQ:PRTO

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time